AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 34598980
Drug: TENS (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TENS (daily home-based for 5 weeks)
Trial: 32589230
Drug: Apixaban (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apixaban (2.5 mg orally twice daily)
Trial: 32589230
Drug: Enoxaparin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin (40 mg subcutaneously daily)
Trial: 36356410
Drug: EVE esc
RxNorm normalized name: Summer's Eve Medicated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EVE esc (2.5 mg/day week 1; 5 mg/day week 2; 7.5 mg/day week 3; 10 mg/day weeks 4-24)
Trial: 36356410
Drug: EVE 10mg
RxNorm normalized name: Summer's Eve Medicated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EVE 10mg (10 mg/day for 24 weeks plus exemestane)
Trial: 37721964
Drug: All treatment
RxNorm normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All treatment regimens
Trial: 32564571
Drug: Clopidogrel 75
RxNorm normalized name: clopidogrel 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 75 mg qd
Trial: 36035935
Drug: Original dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Original dose of neurohumoral blockades
Trial: 36035935
Drug: Halved dose
RxNorm normalized name: VALVE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Halved dose of neurohumoral blockades
Trial: 36035935
Drug: Both doses
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both doses of neurohumoral blockades
Trial: 36042633
Drug: Phellinus linteus
RxNorm normalized name: PHELLINUS LINTEUS WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phellinus linteus extract (1000 mg per day for 8 weeks)
Trial: 36042633
Drug: Placebo (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (1000 mg dextrin per day for 8 weeks)
Trial: 34023318
Drug: Personalized-dose corticosteroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalized-dose corticosteroid therapy for 5 days
Trial: 34023318
Drug: Fixed-dose corticosteroid
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose corticosteroid therapy (40 mg of prednisolone) for 5 days
Trial: 34023318
Drug: Personalized-dose corticosteroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalized-dose corticosteroid therapy
Trial: 34023318
Drug: Fixed-dose corticosteroid
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose corticosteroid therapy
Trial: 34023318
Drug: Personalized-dose corticosteroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalized-dose corticosteroid therapy (40 mg or less)
Trial: 34023318
Drug: Personalized-dose corticosteroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalized-dose corticosteroid therapy (more than 40 mg)
Trial: 33032560
Drug: Absorbable skin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Absorbable skin suture with closure of the subcutaneous fascia (Group 4)
Trial: 33032560
Drug: Non-absorbable skin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-absorbable skin suture with closure of the subcutaneous fascia (Group 3)
Trial: 33032560
Drug: Absorbable skin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Absorbable skin suture without closure of the subcutaneous fascia (Group 2)
Trial: 33032560
Drug: Non-absorbable skin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-absorbable skin suture without closure of the subcutaneous fascia (Group 1)
Trial: 33890902
Drug: Silver sulfadiazine
RxNorm normalized name: Silver Sulfadiazine
DrugBank: Silver sulfadiazine (DB05245)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silver sulfadiazine cream 1%
Trial: 616886766
Drug: Modified Sanxiang
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified Sanxiang Xiaopi decoction (80 mL through a stomach tube for 14 days)
Trial: 33917503
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Lactoplantibacillus plantarum strains CECT7527, CECT7528, and CECT7529 plus 10 mg of monacolin K
Trial: 32163723
Drug: Percentage time
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Percentage time in glucose target 70-180 mg/dL
Trial: 33632215
Drug: Digital information
RxNorm normalized name: INFORMATION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digital information tool with VR-technology and standard care (oral and written information)
Trial: 33632215
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care and information (oral and written)
Trial: 34741564
Drug: Control (rescue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (rescue therapy)
Trial: 32762725
Drug: Functional ability
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Functional ability on ADL (Activities of Daily Living)
Trial: 32762725
Drug: Functional ability
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Functional ability on IADL (Instrumental Activities of Daily Living)
Trial: 35032443
Drug: Daily bathing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily bathing with 2% chlorhexidine gluconate (CHG) detergent solution
Trial: 35032443
Drug: Daily bathing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily bathing with pH neutral soap and water
Trial: 33865308
Drug: Balance exercises
RxNorm normalized name: Rebalance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balance exercises during daily tooth brushing (twice daily for three minutes over eight weeks)
Trial: 36096771
Drug: High molecular
RxNorm normalized name: dextran, high molecular weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High molecular weight hyaluronic acid (HA) injections
Trial: 36096771
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of PRP and HA injections (PRP+HA)
Trial: 35109584
Drug: Multimodal personalized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal personalized lifestyle intervention (dietary and physical activity counseling and cognitive training) combined with dietary supplement epigallocatechin gallate (EGCG)
Trial: 32873263
Drug: BPB (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BPB (100 g)
Trial: 32873263
Drug: PB (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PB (100 g)
Trial: 33813559
Drug: Omidenepag isopropyl
RxNorm normalized name: Omidenepag isopropyl
DrugBank: Omidenepag isopropyl (DB15071)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Omidenepag isopropyl 0.002% once daily (QD)
Trial: 33813559
Drug: Omidenepag isopropyl
RxNorm normalized name: Omidenepag isopropyl
DrugBank: Omidenepag isopropyl (DB15071)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Omidenepag isopropyl 0.002% twice daily (BID)
Trial: 32696102
Drug: Topical tobramycin
RxNorm normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Topical tobramycin 0.3%/dexamethasone 0.1% plus ozonized oil eye drops, four times daily for seven days
Trial: 32696102
Drug: Topical tobramycin
RxNorm normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Topical tobramycin 0.3%/dexamethasone 0.1% eye drops, four times daily for seven days
Trial: 32696102
Drug: Topical tobramycin
RxNorm normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Topical tobramycin 0.3%/dexamethasone 0.1% plus ozonized oil eye drops
Trial: 32696102
Drug: Topical tobramycin
RxNorm normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Topical tobramycin 0.3%/dexamethasone 0.1% eye drops
Trial: 34161053
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy followed by cytoreductive surgery/hyperthermic intraperitoneal chemotherapy and adjuvant chemotherapy
Trial: 32916500
Drug: 17 G
RxNorm normalized name: lancets 17 gauge MISCELL EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17 G needle
Trial: 32916500
Drug: 18 G
RxNorm normalized name: flotufolastat F 18 gallium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18 G needle
Trial: 35915512
Drug: TAU+ (treatment‐as‐usual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAU+ (treatment‐as‐usual plus fitness tracker)
Trial: 38775255
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 1200 mg
Trial: 32559794
Drug: Juice group
RxNorm normalized name: tamarind juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Juice group (200 mL of liquid enriched with carbohydrate and protein 4 hours presurgery)
Trial: 32559794
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (200 mL of inert solution 4 hours presurgery)
Trial: 34592862
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg oral thiamine for 12 weeks
Trial: 34592862
Drug: Over-the-counter (OTC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Over-the-counter (OTC) oral thiamine after 6 months
Trial: 33693586
Drug: Oral antipseudomonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antipseudomonal antibiotics
Trial: 33693586
Drug: Intravenous antipseudomonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous antipseudomonal antibiotics
Trial: 33693586
Drug: Inhaled antipseudomonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled antipseudomonal antibiotics
Trial: 33849629
Drug: SARS-CoV-2 vaccine
RxNorm normalized name: SARS-CoV-2 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SARS-CoV-2 vaccine (inactivated, Vero cell)
Trial: 32703746
Drug: 5-dose MCV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-dose MCV vials
Trial: 32703746
Drug: 10-dose MCV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-dose MCV vials
Trial: 34596156
Drug: Pulsed magnetic
RxNorm normalized name: MAGNESIA
DrugBank: Magnesium oxide (DB01377)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pulsed magnetic therapy
Trial: 34596156
Drug: Combined magnetic
RxNorm normalized name: MAGNESIA
DrugBank: Magnesium oxide (DB01377)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combined magnetic therapy and exercise therapy
Trial: 34596156
Drug: Routine medical
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine medical treatment (Control)
Trial: 35917985
Drug: Triple antibiotic
RxNorm normalized name: Triple Antibiotic
DrugBank: Polymyxin B (DB00781)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triple antibiotic paste, Calcium Hydroxide, and Saline
Trial: 32394653
Drug: Electroacupuncture (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroacupuncture (EA) at Neiguan (PC 6) and Shuigou (GV 26) with disperse-dense wave, 2 Hz/100 Hz in frequency, 0.1-5 mA in intensity, treatment performed once a day for 14 consecutive days.
Trial: 32394653
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group treated with awakening drugs and neurotrophic drugs.
Trial: 32406162
Drug: Microneedling plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microneedling plus topical 4% tranexamic acid
Trial: 32406162
Drug: Topical 4%
RxNorm normalized name: menthol topical 4% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 4% hydroquinone
Trial: 35715486
Drug: Daily mother-infant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily mother-infant skin-to-skin contact (SSC) for one hour during the first five postnatal weeks
Trial: 35715486
Drug: Daily mother-infant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily mother-infant skin-to-skin contact (SSC) (per-protocol analysis)
Trial: 35715486
Drug: Daily mother-infant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily mother-infant skin-to-skin contact (SSC)
Trial: 33751906
Drug: l-theanine (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-theanine (single dose)
Trial: 33751906
Drug: l-theanine (regular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-theanine (regular intake for 12 weeks)
Trial: 35869143
Drug: Subsequent therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subsequent therapies
Trial: 37495797
Drug: Drug-coated balloons
RxNorm normalized name: erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug-coated balloons (DCB)
Trial: 34096661
Drug: Cranial microcurrent
RxNorm normalized name: geranial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cranial microcurrent stimulation (CMS); intensity, 25 μA; frequency, 8 Hz; 20-minute daily treatment for 2 weeks.
Trial: 34096661
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment (no current).
Trial: 35698001
Drug: Alfentanil 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil 0.2 μg/kg/min
Trial: 35698001
Drug: Alfentanil 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil 0.4 μg/kg/min
Trial: 35698001
Drug: Alfentanil 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil 0.2 μg/kg/min vs Normal saline
Trial: 36243712
Drug: Starch tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starch tablets (Control)
Trial: 33370476
Drug: Digital grayscale
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digital grayscale intra-oral scans
Trial: 39587622
Drug: Saline (placebo)
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline (placebo) injection
Trial: 33504040
Drug: Mirror Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirror Therapy Action Observation (MTAO)
Trial: 39599964
Drug: Action Observation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Action Observation Therapy (AOT)
Trial: 32881835
Drug: Resveratrol supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resveratrol supplementation (75 mg BID)
Trial: 32742515
Drug: Haloperidol (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (0.5 cc, 5 mg)
Trial: 32742515
Drug: Metoclopramide (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide (10 mg, given 30 minutes before surgery)
Trial: 32742515
Drug: Dexmedetomidine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (25 μg)
Trial: 32742515
Drug: Ginger (four
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginger (four capsules with a hint of lemon)
Trial: 35683427
Drug: Convalescent plasma
RxNorm normalized name: Convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Convalescent plasma (600 mL divided into two doses administered on days 1 and 2)
Trial: 35683427
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment alone (Control group)
Trial: 32873093
Drug: Morning BTA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morning BTA injections
Trial: 32873093
Drug: Afternoon BTA
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Afternoon BTA injections
Trial: 35028684
Drug: Conventional contrast
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional contrast material (CM) injection protocol based on body weight
Trial: 35523495
Drug: Transdermal electrical
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal electrical stimulation (TdES) with skin electrodes
Trial: 33580809
Drug: Preoperative pelvic
RxNorm normalized name: Sus scrofa renal pelvis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative pelvic floor muscle training (PFMT) daily from inclusion to the day of surgery
Trial: 35166373
Drug: Oral paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral paracetamol (0.6 ml.kg‐1, 24 mg.ml‐1 concentration)
Trial: 35166373
Drug: Water alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water alone (3.6 ml.kg‐1)
Trial: 36200545
Drug: Percutaneous treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Percutaneous treatment (35.0% in 2020 vs. 25.9% in 2019; p < 0.0001)
Trial: 35664492
Drug: Venlafaxine 150
RxNorm normalized name: venlafaxine 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine 150 mg daily
Trial: 33261932
Drug: Esketamine nasal
RxNorm normalized name: esketamine Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esketamine nasal spray combined with a new oral antidepressant (AD)
Trial: 33261932
Drug: Placebo combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo combined with a new oral antidepressant (AD)
Trial: 32756846
Drug: Chemical weeding
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemical weeding treatments
Trial: 33354815
Drug: 0.15 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.15 mg/kg intravenous subdissociative ketamine (low dose)
Trial: 33354815
Drug: 0.30 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.30 mg/kg intravenous subdissociative ketamine (high dose)
Trial: 37395841
Drug: Mindfulness-based therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-based therapy
Trial: 36180944
Drug: Liver transplantation
RxNorm normalized name: LIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liver transplantation (LT) + best established treatment (BET)
Trial: 36180944
Drug: Best established
RxNorm normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best established treatment (BET) only
Trial: 34624138
Drug: Myo-inositol and
RxNorm normalized name: myo-inositol
DrugBank: Inositol (DB13178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Myo-inositol and d-chiro-inositol combination (MI + DCI) 550 + 150 mg, twice a day for 6 months
Trial: 34624138
Drug: Combined hormonal
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combined hormonal contraceptive (CHC) (ethinyl estradiol 20 µg + drospirenone 3 mg), once a day for 6 months
Trial: 32703216
Drug: AA mixture
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AA mixture containing 1.8 g of arginine, 1.1 g of valine, and 0.1 g of serine
Trial: 32271637
Drug: Oral isotretinoin
RxNorm normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral isotretinoin alone at a dose of 0.3 mg/kg/day
Trial: 32271637
Drug: Candida antigen
RxNorm normalized name: Candida antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candida antigen alone at a dose of 0.1 ml of 1/1000 solution into the largest wart
Trial: 32271637
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Candida antigen and oral isotretinoin by the same method and dose
Trial: 33187759
Drug: Interim methadone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interim methadone treatment plus patient navigation (IM + PN)
Trial: 33187759
Drug: Interim methadone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interim methadone treatment (IM)
Trial: 32359668
Drug: Enhanced Treatment-as-Usual
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced Treatment-as-Usual (ETAU)
Trial: 35679902
Drug: All treatment
RxNorm normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All treatment groups (HA, PRP, HA+PRP)
Trial: 34409891
Drug: HAD-B1 (972
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HAD-B1 (972 mg)
Trial: 34409891
Drug: HAD-B1 (1944
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HAD-B1 (1944 mg)
Trial: 32246262
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of biomarkers including carnosine
Trial: 35679775
Drug: Continuous positive
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous positive airway pressure (CPAP) treatment
Trial: 36162887
Drug: Low-Level Laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-Level Laser Therapy (LLLT) with diode laser (980 nm, 100 mW for 1 minute)
Trial: 33986125
Drug: Ipilimumab administered
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ipilimumab administered immediately after sipuleucel-T
Trial: 33986125
Drug: Ipilimumab administered
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ipilimumab administered delayed 3 weeks after sipuleucel-T
Trial: 33986125
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment of sipuleucel-T and ipilimumab
Trial: 33986125
Drug: Prior localized
RxNorm normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prior localized radiation therapy (RT)
Trial: 34969423
Drug: Integrated intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integrated intervention using behavioural counselling with nicotine replacement therapy (NRT) gum